20-Sep-2011 Source: CareFusion
CareFusion (NYSE: CFN), a leading global medical technology company, today announced the launch of the ReVelâ„¢ ventilator, a new high performance, portable device designed for pediatric to adult (min. 5Kg) patients who require breathing support during transport.
The ReVel ventilator is a complementary addition to CareFusionâ€™s Alternate Care portfolio, including emergency and military respiratory care, which is focused on helping clinicians improve patient care, optimizing ventilator therapy and reducing costs. Specifically, the ReVel has the capability to manage the most critical, intubated and non-invasively ventilated patients from the initial point of emergency, during transport and through the hospital allowing for potentially lifesaving ventilation during transport. The ReVel weighs 9.5 pounds compared to the typical 20+ pound systems. Its small size and ergonomic design mounts easily in ground and air emergency vehicles, including ambulances, helicopters and military aircraft.
The ReVel is the second palm top ventilator to be released by CareFusion. In December 2010, CareFusion launched the first in its series, the EnVeÂ® ventilator, a high-performance critical care device that weighs 9.5 pounds, more than 70-80 pounds lighter than other ventilators with similar functions. The ReVel and EnVe ventilators are engineered with CareFusion’s patented ActivCoreâ„¢ gas delivery systemâ€”the basis for their powerful, compact design. The palm top ventilator technology provides high-end critical care ventilation and independence from wall-air systems and features a hot swappable four-hour battery for extended patient transport capabilities.
“Unlike previous generations of emergency transport ventilators, the ReVel allows clinicians to provide pediatric and adult patients with the highest level of care with a light-weight and portable system through the continuum of care,” said Kevin Ketzel, general manager for Respiratory Technologies at CareFusion.. “By delivering critical care capabilities from the onset of emergency transport, clinicians can better manage and care for high-acuity patients in medical transit allowing the transport team to focus on the patient’s emergency medical needs.”
The ReVel ventilator also provides monitoring and clinical tools to assist clinicians in best managing and caring for patients in hospital or alternate care facilities. Its Spontaneous Breathing Trial (SBT) technology provides data to help clinicians decide when to safely wean patients from ventilation. The device also features an integrated pulse oximeter to monitor a patient’s pulse rate and oxygen saturation level during transport situations in lieu of costly additional equipment.
The ReVel ventilator is available in the U.S. For more information, please visitÂ www.carefusion.com/revel.
CareFusion (NYSE: CFN) is a global corporation serving the health care industry with products and services that help hospitals measurably improve the safety and quality of care. The company develops market-leading technologies including AlarisÂ® infusion pumps, PyxisÂ® automated dispensing and patient identification systems, AVEAÂ®, AirLifeâ„¢ and LTVÂ® series ventilation and respiratory products, ChloraPrepÂ® products, MedMinedâ„¢ services for data mining surveillance, Nicoletâ„¢ neurological monitoring and diagnostic products, V. MuellerÂ® surgical instruments, and an extensive line of products that support interventional medicine. CareFusion employs more than 14,000 people across its global operations. More information may be found atÂ www.carefusion.com.